SAB Bio (SAB Biotherapeutics, Inc.) recently released further data from a Phase I clinical trial of its candidate drug SAB-142 in adult patients diagnosed with autoimmune type 1 diabetes.
Show original
This data update provides additional support information for the clinical development of this drug.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
PoolX: Earn new token airdrops
Lock your assets and earn 10%+ APR
Lock now!
You may also like
Trending news
MoreCrypto prices
More
Bitcoin
BTC
$70,491.49
+3.36%
Ethereum
ETH
$2,048.95
+2.25%
Tether USDt
USDT
$1
+0.01%
BNB
BNB
$646.48
+2.43%
XRP
XRP
$1.39
+2.57%
USDC
USDC
$1.0000
-0.01%
Solana
SOL
$86.7
+3.23%
TRON
TRX
$0.2848
-0.08%
Dogecoin
DOGE
$0.09487
+4.48%
Cardano
ADA
$0.2638
+3.24%
How to buy BTC
Bitget lists BTC – Buy or sell BTC quickly on Bitget!
Trade now
Become a trader now?A welcome pack worth 6200 USDT for new users!
Sign up now